RESTON, Va., July 8 /PRNewswire/ -- BSI announced today that Repligen Corporation, Waltham, MA (Nasdaq: RGEN); the world's leading supplier of recombinant Protein A, a consumable used in the manufacture of monoclonal antibodies, the fastest growing segment of the biopharmaceutical industry has achieved BS 25999 certification. Repligen is the first company in North America to have achieved certification for their commitment to ensuring business continuity in the event of disaster or disruption.
BS 25999 is a visionary standard designed to keep your business going during the most challenging and unexpected circumstances. It provides a basis for understanding, developing, implementing and managing business continuity within your organization and gives you confidence when dealing with stakeholders both within and outside your organization. BS 25999 is an auditable standard which means that through certification, you have a framework for continual improvement and the ability to demonstrate to your stakeholders that your BCM program meets globally accepted best practice.
"By earning BS 25999 certification, Repligen is clearly demonstrating their commitment to ensure continued operation in the face of any potential cause of business disruption," said Gary Pearsons, President of BSI Management Systems. "Repligen is the first company in North America to achieve BS 25999 certification. This is just one more example of the leadership role Repligen has earned in their industry. Through the combined strength of Repligen implementing a disciplined management system and BSI providing independent verification and certification; Repligen's stakeholders and customers can be assured of the resiliency of their operations."
"Repligen is at the head of a long and growing list of leading-edge companies wishing to prove that they are doing what is required to protect their businesses, their stakeholders, and their customers," Pearsons added.
"As the world's leading supplier of recombinant Protein A, we felt that
it was important to be on the cutting edge of business continuity to ensure
an uninterrupted supply of products to our customers and ultimately to
patients," stated Walter C. Herlihy, President and Chief Executive Officer
of Repligen Corporation. "Implementation of and certification to BS 25999
has helped Repligen become more resilient, and agile by providing valuable
insight into the issues and challenges that we may face in the event of a
business interruption. We are very proud to be the first company in North
America to have gained certification."
BSI Management Systems
About BSI Management Systems
BSI Management Systems is one of the world's largest certification
bodies, with over 60,000 certified locations and clients in more than 100
countries. Operating through a global network, BSI Management Systems
provides assessment, certification and training services in all critical
areas of management disciplines including:
-- Business Continuity
-- Food Safety
-- Health & Safety
-- Information Security
-- Integrated Management
-- Social Accountability
-- Sustainable Development
-- IT Service Management
About Repligen and Recombinant Protein A
Repligen is the world's leading supplier of recombinant Protein A, a consumable used in the manufacture of monoclonal antibodies. There are approximately 20 monoclonal antibodies that have received regulatory approval with more than 200 products in various stages of clinical development. The worldwide revenues from this class of drug exceeded $20 billion in 2006 and are forecast to exceed $30 billion in 2010. Monoclonal antibodies are the largest and fastest growing class of drug in the biopharmaceutical industry. (http://www.repligen.com)
|SOURCE BSI Management Systems|
Copyright©2008 PR Newswire.
All rights reserved